Browsing by Author "Hegen, Harald (57202373490)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders(2014) ;Gnanapavan, Sharmilee (7801629497) ;Hegen, Harald (57202373490) ;Khalil, Michael (55628524072) ;Hemmer, Bernhard (7005721046) ;Franciotta, Diego (7003954703) ;Hughes, Steve (56450036000) ;Hintzen, Rogier (26643157200) ;Jeromin, Andreas (57215443325) ;Havrdova, Eva (57201596736) ;Tumani, Hayrettin (7003596212) ;Bertolotto, Antonio (7006458938) ;Comabella, Manuel (6701491362) ;Frederiksen, Jette (7102315536) ;Álvarez-Cermeño, José C. (7004605927) ;Villar, Luisa (35518965300) ;Galimberti, Daniela (6701617660) ;Myhr, Kjell-Morten (7005382096) ;Dujmovic, Irena (6701590899) ;Fazekas, Franz (7102945505) ;Ionete, Carolina (7102976852) ;Menge, Til (6505932679) ;Kuhle, Jens (8937520800) ;Keir, Geoffrey (7003356165) ;Deisenhammer, Florian (7004758773) ;Teunissen, Charlotte (6701704380)Giovannoni, Gavin (34770127900)Objective: The aim of these guidelines is to make the process of reporting body fluid biomarker studies in neurologic disorders more uniform and transparent, in line with existing standards for reporting research in other biomedical areas. Although biomarkers have been around for decades, there are concerns over the high attrition rate of promising candidate biomarkers at later phases of development. Methods: BioMS-eu consortium, a collaborative network working toward improving the quality of biomarker research in neurologic disorders, discussed the merits of standardizing the reporting of body fluid biomarker research. A checklist of items integrating the results of other published guidances, literature, conferences, regulatory opinion, and personal expertise was created to ultimately form a structured summary guidance incorporating the key features. Results: The summary guidance is comprised of a 10-point uniform reporting format ranging from introduction, materials and methods, through to results and discussion. Each item is discussed in detail in the guidance report. Conclusions: To enhance the future development of body fluid biomarkers, it will be important to standardize the reporting of studies. This guideline by the BioMS-eu consortium is aimed at setting a standard for the reporting of future body fluid biomarker research studies in neurologic disorders. We anticipate that following these guidelines will help to accelerate the selection of biomarkers for clinical development. © 2014 American Academy of Neurology. - Some of the metrics are blocked by yourconsent settings
Publication Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders(2022) ;Habek, Mario (14050219000) ;Andabaka, Marko (57207949404) ;Fanciulli, Alessandra (37072222700) ;Brecl Jakob, Gregor (56545621600) ;Drulović, Jelena (55886929900) ;Leys, Fabian (57216857911) ;Di Pauli, Franziska (25947452900) ;Hegen, Harald (57202373490) ;Auer, Michael (56566208600) ;Pekmezović, Tatjana (7003989932) ;Mesaroš, Šarlota (7004307592) ;Jovičević, Vanja (57306237100) ;Junaković, Anamari (55252791400) ;Wenning, Gregor K. (21647300300) ;Deisenhammer, Florian (7004758773) ;Gabelić, Tereza (15131714000) ;Barun, Barbara (24780632600) ;Adamec, Ivan (41261161500)Krbot Skorić, Magdalena (55915654300)Background and purpose: The aim was to determine the extent of sudomotor dysfunction in people with neuromyelitis optica spectrum disorder (pwNMOSD) and to compare findings with a historical cohort of people with relapsing–remitting multiple sclerosis (pwRRMS). Methods: Forty-eight pwNMOSD were enrolled from four clinical centers. All participants completed the Composite Autonomic Symptom Score 31 to screen for symptoms of sudomotor dysfunction. Sudomotor function was assessed using the quantitative sudomotor axon reflex test. The results were compared with a historical cohort of 35 pwRRMS matched for age, sex and disease duration. Results: Symptoms of sudomotor dysfunction, defined by a score in the Composite Autonomic Symptom Score 31 secretomotor domain >0, were present in 26 (54%) of pwNMOSD. The quantitative sudomotor axon reflex test confirmed a sudomotor dysfunction in 25 (52.1%) of pwNMOSD; in 14 of them (29.2%) sudomotor dysfunction was moderate or severe. No difference was observed between pwNMOSD and pwRRMS in any of the studied parameters. However, symptomatic sudomotor dysfunction was more frequent in pwNMOSD (n = 8, 22.9%) compared to pwRRMS (n = 1, 3%; p = 0.028). In a multivariable logistic regression analysis, statistically significant predictors for symptomatic sudomotor failure were age and diagnosis of neuromyelitis optica spectrum disorder. Conclusions: Sudomotor dysfunction is common in pwNMOSD and more often symptomatic compared to pwRRMS. © 2022 European Academy of Neurology. - Some of the metrics are blocked by yourconsent settings
Publication Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders(2022) ;Habek, Mario (14050219000) ;Andabaka, Marko (57207949404) ;Fanciulli, Alessandra (37072222700) ;Brecl Jakob, Gregor (56545621600) ;Drulović, Jelena (55886929900) ;Leys, Fabian (57216857911) ;Di Pauli, Franziska (25947452900) ;Hegen, Harald (57202373490) ;Auer, Michael (56566208600) ;Pekmezović, Tatjana (7003989932) ;Mesaroš, Šarlota (7004307592) ;Jovičević, Vanja (57306237100) ;Junaković, Anamari (55252791400) ;Wenning, Gregor K. (21647300300) ;Deisenhammer, Florian (7004758773) ;Gabelić, Tereza (15131714000) ;Barun, Barbara (24780632600) ;Adamec, Ivan (41261161500)Krbot Skorić, Magdalena (55915654300)Background and purpose: The aim was to determine the extent of sudomotor dysfunction in people with neuromyelitis optica spectrum disorder (pwNMOSD) and to compare findings with a historical cohort of people with relapsing–remitting multiple sclerosis (pwRRMS). Methods: Forty-eight pwNMOSD were enrolled from four clinical centers. All participants completed the Composite Autonomic Symptom Score 31 to screen for symptoms of sudomotor dysfunction. Sudomotor function was assessed using the quantitative sudomotor axon reflex test. The results were compared with a historical cohort of 35 pwRRMS matched for age, sex and disease duration. Results: Symptoms of sudomotor dysfunction, defined by a score in the Composite Autonomic Symptom Score 31 secretomotor domain >0, were present in 26 (54%) of pwNMOSD. The quantitative sudomotor axon reflex test confirmed a sudomotor dysfunction in 25 (52.1%) of pwNMOSD; in 14 of them (29.2%) sudomotor dysfunction was moderate or severe. No difference was observed between pwNMOSD and pwRRMS in any of the studied parameters. However, symptomatic sudomotor dysfunction was more frequent in pwNMOSD (n = 8, 22.9%) compared to pwRRMS (n = 1, 3%; p = 0.028). In a multivariable logistic regression analysis, statistically significant predictors for symptomatic sudomotor failure were age and diagnosis of neuromyelitis optica spectrum disorder. Conclusions: Sudomotor dysfunction is common in pwNMOSD and more often symptomatic compared to pwRRMS. © 2022 European Academy of Neurology.
